艾滋病毒感染者接种首剂严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗的安全性和抗体反应。
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
机构信息
Department of Surgery.
Division of Infectious Diseases, Department of Medicine.
出版信息
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
Abstract
In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.
摘要
在这项研究中，12 名 HIV 感染者（PWH）接种了第一剂 SARS-CoV-2 mRNA 疫苗，所有参与者均可检测到抗 SARS-CoV-2 受体结合域抗体；CD4+计数较低者的抗体水平较低，疫苗反应通常较轻。
相似文献
1
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.艾滋病毒感染者接种首剂严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗的安全性和抗体反应。
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
2
Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.严重免疫抑制的HIV感染者对SARS-CoV-2疫苗加强针的中和抗体反应降低。
J Med Virol. 2023 Mar;95(3):e28602. doi: 10.1002/jmv.28602.
3
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.HIV 感染者两剂次 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体应答。
AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017.
4
Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.在 HIV 感染者中，不同的 SARS-CoV-2 疫苗平台可诱导产生稳健的疫苗诱导的体液免疫和细胞免疫反应。
Microbiol Spectr. 2023 Jun 15;11(3):e0115523. doi: 10.1128/spectrum.01155-23. Epub 2023 May 11.
5
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.人免疫缺陷病毒感染者对严重急性呼吸综合征冠状病毒 2 mRNA 疫苗的抗体反应的决定因素。
AIDS. 2022 Aug 1;36(10):1465-1468. doi: 10.1097/QAD.0000000000003246. Epub 2022 Jul 9.
6
Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.严重的免疫抑制与艾滋病毒感染者对 SARS-CoV-2 疫苗的免疫原性较差有关。
Clin Microbiol Infect. 2022 Nov;28(11):1492-1498. doi: 10.1016/j.cmi.2022.05.018. Epub 2022 May 28.
7
Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?对常规抗病毒疫苗的抗体反应不理想的个体能否从 SARS-CoV-2 mRNA 疫苗接种中获得足够的抗体？
Viruses. 2022 May 3;14(5):956. doi: 10.3390/v14050956.
8
Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.养老院中初次接触严重急性呼吸综合征冠状病毒2的居民对BioNTech/辉瑞2019冠状病毒病疫苗的抗体反应较差。
Clin Infect Dis. 2022 Aug 24;75(1):e695-e704. doi: 10.1093/cid/ciab998.
9
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.在免疫重建不良的 HIV 感染者中，SARS-CoV-2 疫苗接种后体液和特异性 T 细胞应答有限。
J Infect Dis. 2022 Nov 28;226(11):1913-1923. doi: 10.1093/infdis/jiac406.
10
Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.弥合差距：确定影响 HIV-1 感染者 mRNA 严重急性呼吸综合征冠状病毒 2 疫苗加强针反应的因素。
AIDS. 2024 Feb 1;38(2):217-222. doi: 10.1097/QAD.0000000000003751. Epub 2023 Oct 11.
引用本文的文献
1
Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.在未接触过该病毒的 HIV 患者和 CD4/CD8 比值正常的人群中，预先存在对 SARS-CoV-2 具有细胞毒性作用的细胞群体。
Front Immunol. 2024 May 15;15:1362621. doi: 10.3389/fimmu.2024.1362621. eCollection 2024.
2
The immune response to SARS-CoV-2 in people with HIV.人类免疫缺陷病毒（HIV）感染者对 SARS-CoV-2 的免疫反应。
Cell Mol Immunol. 2024 Feb;21(2):184-196. doi: 10.1038/s41423-023-01087-w. Epub 2023 Oct 11.
3
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.新型冠状病毒肺炎疫苗的免疫原性及其对老年艾滋病毒感染者体内艾滋病毒储存库的影响。
iScience. 2023 Sep 14;26(10):107915. doi: 10.1016/j.isci.2023.107915. eCollection 2023 Oct 20.
4
Advances in Research on COVID-19 Vaccination for People Living with HIV.针对艾滋病毒感染者的新冠疫苗接种研究进展
Infect Dis Immun. 2022 Oct;2(4):213-218. doi: 10.1097/ID9.0000000000000065. Epub 2022 Sep 1.
5
Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV.2019冠状病毒病疫苗的免疫原性及其对老年HIV感染者体内HIV储存库的影响。
bioRxiv. 2023 Jun 15:2023.06.14.544834. doi: 10.1101/2023.06.14.544834.
6
Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.HIV 感染者接种 COVID-19 疫苗后的血清学反应：剂量反应荟萃分析。
Sci Rep. 2023 Jun 19;13(1):9893. doi: 10.1038/s41598-023-37051-x.
7
Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis.HIV感染的COVID-19疫苗接种患者CD4 T细胞计数与血清转化之间的相关性：一项荟萃分析。
Vaccines (Basel). 2023 Apr 4;11(4):789. doi: 10.3390/vaccines11040789.
8
Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV.HIV 感染者的 SARS-CoV-2 疫苗接种的免疫原性、有效性和安全性。
AIDS. 2023 Jul 15;37(9):1345-1360. doi: 10.1097/QAD.0000000000003579. Epub 2023 Apr 13.
9
The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.两剂科兴疫苗接种的安全性和免疫原性，以及在 HIV 感染者中接种疫苗六个月后的免疫持久性：一项多中心前瞻性队列研究。
Front Immunol. 2023 Mar 13;14:1129651. doi: 10.3389/fimmu.2023.1129651. eCollection 2023.
10
Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.HIV 感染者对 BNT162b2 SARS-CoV-2 疫苗的免疫应答：COVIH-DAPT 研究。
Front Immunol. 2023 Mar 6;14:1136723. doi: 10.3389/fimmu.2023.1136723. eCollection 2023.
本文引用的文献
1
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
2
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
3
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.实体器官移植受者中首剂严重急性呼吸综合征冠状病毒2疫苗接种的安全性
Transplantation. 2021 May 1;105(5):e56-e57. doi: 10.1097/TP.0000000000003654.
4
Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation.抗SARS-CoV-2抗体的定量检测：分析与临床评估
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.03149-20.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
6
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
7
COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV.新冠疫情相关的医疗不信任、对健康的影响，以及黑人群体中艾滋病毒感染者对疫苗的潜在犹豫。
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):200-207. doi: 10.1097/QAI.0000000000002570.
8
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
9
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
10
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.评估 mRNA-1273 疫苗对 SARS-CoV-2 在非人类灵长类动物中的效果。
N Engl J Med. 2020 Oct 15;383(16):1544-1555. doi: 10.1056/NEJMoa2024671. Epub 2020 Jul 28.
Zotero 插件